Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Weighted Average and Diluted) (2021 - 2025)

Historic EPS (Weighted Average and Diluted) for Cyclerion Therapeutics (CYCN) over the last 5 years, with Q3 2025 value amounting to -$0.31.

  • Cyclerion Therapeutics' EPS (Weighted Average and Diluted) changed N/A to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.31, marking a year-over-year increase of 7375.23%. This contributed to the annual value of $3.14 for FY2023, which is 12637.31% up from last year.
  • Cyclerion Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.31 in Q3 2025.
  • In the past 5 years, Cyclerion Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $4.84 in Q3 2023 and a low of -$6.16 during Q2 2022
  • For the 5-year period, Cyclerion Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.96, with its median value being -$0.55 (2024).
  • Per our database at Business Quant, Cyclerion Therapeutics' EPS (Weighted Average and Diluted) plummeted by 126888.89% in 2022 and then skyrocketed by 27267.48% in 2023.
  • Cyclerion Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.24 in 2021, then crashed by 454.72% to -$1.33 in 2022, then surged by 463.27% to $4.84 in 2023, then plummeted by 111.4% to -$0.55 in 2024, then skyrocketed by 43.43% to -$0.31 in 2025.
  • Its last three reported values are -$0.31 in Q3 2025, -$0.54 for Q2 2025, and -$0.57 during Q1 2025.